Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 8,888,888 | $231,022,199 | +4% | 3.07% |
| 2. | Slate Path Capital David Greenspan | 4,139,000 | $107,572,610 | 2.04% | |
| 3. | Citadel Investment Group Ken Griffin | 948,444 | $24,650,059 | +28% | 0% |
| 4. | Rokos Capital Management Chris Rokos | 939,984 | $24,410,662 | -24% | 0.15% |
| 5. | Aquilo Capital Management Marc Schneidman | 908,474 | $23,611,239 | 22.76% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.50 | 1,000 | Director | 33,680 | 2024-03-20 | Filing | |
| $28.00 | 1,000 | Director | 32,680 | 2024-03-19 | Filing | |
| $27.49 | 1,000 | Director | 31,680 | 2024-03-18 | Filing | |
| $66.37 | 655 | Director | 109,868 | 2021-12-28 | Filing | |
| $50.00 | 500 | Director | 17,500 | 2020-10-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.28 | 9,394 | Officer | 127,107 | 2024-07-02 | Filing | |
| $23.31 | 1,799 | Director | 30,205 | 2024-05-02 | Filing | |
| $28.03 | 6,000 | Officer | 204,851 | 2024-04-01 | Filing | |
| $35.19 | 40,000 | Officer | 400,600 | 2024-03-06 | Filing | |
| $32.71 | 19,730 | Officer, Director | 3,715,048 | 2024-01-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,303,757 | $407,094,965 | 0.01% | |
| 2. | 10,672,076 | $326,565,525 | 0% | |
| 3. | 6,825,111 | $208,848,397 | 0.01% | |
| 4. | 3,371,268 | $103,160,815 | 0% | |
| 5. | 2,751,048 | $84,182,068 | 0% |
News See All
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.78.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.